132 related articles for article (PubMed ID: 32757802)
1. Apigenin Enhanced Antitumor Effect of Cisplatin in Lung Cancer via Inhibition of Cancer Stem Cells.
Li Y; Chen X; He W; Xia S; Jiang X; Li X; Bai J; Li N; Chen L; Yang B
Nutr Cancer; 2021; 73(8):1489-1497. PubMed ID: 32757802
[TBL] [Abstract][Full Text] [Related]
2. Increased PD-L1 Expression in Acquired Cisplatin-Resistant Lung Cancer Cells via Mir-181a.
Chen Y; Song W; Gao Y; Dong X; Ji X
Tohoku J Exp Med; 2022 May; 257(1):33-43. PubMed ID: 35354691
[TBL] [Abstract][Full Text] [Related]
3. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway.
Jiang P; Xu H; Xu C; Chen A; Chen L; Zhou M; Haq IU; Wu X; Mariyam Z; Feng Q
Chem Biol Interact; 2018 Dec; 296():154-161. PubMed ID: 30291867
[TBL] [Abstract][Full Text] [Related]
4. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
5. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
[TBL] [Abstract][Full Text] [Related]
6. Synergistic anticancer effect of combined use of Trichosanthes kirilowii with cisplatin and pemetrexed enhances apoptosis of H1299 non-small-cell lung cancer cells via modulation of ErbB3.
Ku JM; Hong SH; Kim HI; Kim MJ; Kim SK; Kim M; Choi SY; Park J; Kim HK; Kim JH; Seo HS; Shin YC; Ko SG
Phytomedicine; 2020 Jan; 66():153109. PubMed ID: 31790894
[TBL] [Abstract][Full Text] [Related]
7. JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1.
Wang Q; Wu J; Wei H; Huang H; Huang Y; Fang H; Gong X; Sun J; Wu Y; Lei C; Yu J; Hu D
Int J Biochem Cell Biol; 2021 Sep; 138():106040. PubMed ID: 34246759
[TBL] [Abstract][Full Text] [Related]
8. Profiling of apoptosis- and autophagy-associated molecules in human lung cancer A549 cells in response to cisplatin treatment using stable isotope labeling with amino acids in cell culture.
Wang Z; Liu G; Jiang J
Int J Oncol; 2019 Mar; 54(3):1071-1085. PubMed ID: 30664195
[TBL] [Abstract][Full Text] [Related]
9. Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma.
Hao C; Liu G; Tian G
Ther Adv Respir Dis; 2019; 13():1753466619866097. PubMed ID: 31368411
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin resistant lung cancer cells promoted M2 polarization of tumor-associated macrophages via the Src/CD155/MIF functional pathway.
Huang WC; Kuo KT; Wang CH; Yeh CT; Wang Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):180. PubMed ID: 31036057
[TBL] [Abstract][Full Text] [Related]
11. EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells.
Jiang P; Xu C; Chen L; Chen A; Wu X; Zhou M; Haq IU; Mariyam Z; Feng Q
Mol Carcinog; 2018 Dec; 57(12):1835-1844. PubMed ID: 30182373
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.
Ren T; Shan J; Li M; Qing Y; Qian C; Wang G; Li Q; Lu G; Li C; Peng Y; Luo H; Zhang S; Yang Y; Cheng Y; Wang D; Zhou SF
Drug Des Devel Ther; 2015; 9():2887-910. PubMed ID: 26089640
[TBL] [Abstract][Full Text] [Related]
13. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
14. Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer.
Yang Y; Zhang P; Zhao Y; Yang J; Jiang G; Fan J
Cancer Biol Ther; 2016 May; 17(5):515-25. PubMed ID: 26492332
[TBL] [Abstract][Full Text] [Related]
15. Different mechanisms of cisplatin resistance development in human lung cancer cells.
Okamoto K; Saito Y; Narumi K; Furugen A; Iseki K; Kobayashi M
Biochem Biophys Res Commun; 2020 Oct; 530(4):745-750. PubMed ID: 32782152
[TBL] [Abstract][Full Text] [Related]
16. PD-0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance.
Liu M; Cui L; Li X; Xia C; Li Y; Wang R; Ren F; Liu H; Chen J
Thorac Cancer; 2021 Mar; 12(6):924-931. PubMed ID: 33534964
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
18. Toosendanin mediates cisplatin sensitization through targeting Annexin A4/ATP7A in non-small cell lung cancer cells.
Zheng MD; Wang ND; Li XL; Yan J; Tang JH; Zhao XH; Zhang Z
J Nat Med; 2018 Jun; 72(3):724-733. PubMed ID: 29627895
[TBL] [Abstract][Full Text] [Related]
19. Elevated pressure, a novel cancer therapeutic tool for sensitizing cisplatin-mediated apoptosis in A549.
Oh S; Kim Y; Kim J; Kwon D; Lee E
Biochem Biophys Res Commun; 2010 Aug; 399(1):91-7. PubMed ID: 20643104
[TBL] [Abstract][Full Text] [Related]
20. ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway.
Lo Iacono M; Monica V; Vavalà T; Gisabella M; Saviozzi S; Bracco E; Novello S; Papotti M; Scagliotti GV
Int J Cancer; 2015 Jun; 136(11):2598-609. PubMed ID: 25359574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]